Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Hypermethylation of Synphilin-1, Alpha-Synuclein-Interacting Protein (SNCAIP) Gene in the Cerebral Cortex of Patients with Sporadic Parkinson's Disease.

Dashtipour K, Tafreshi A, Adler C, Beach T, Chen X, Serrano G, Tashiro S, Wang C.

Brain Sci. 2017 Jun 27;7(7). pii: E74. doi: 10.3390/brainsci7070074.

2.

RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials.

Dashtipour K, Bhidayasiri R, Chen JJ, Jabbari B, Lew M, Torres-Russotto D.

J Clin Mov Disord. 2017 Jun 6;4:9. doi: 10.1186/s40734-017-0055-1. eCollection 2017. Review.

3.

Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial.

Wharen RE Jr, Okun MS, Guthrie BL, Uitti RJ, Larson P, Foote K, Walker H, Marshall FJ, Schwalb J, Ford B, Jankovic J, Simpson R, Dashtipour K, Phibbs F, Neimat JS, Stewart RM, Peichel D, Pahwa R, Ostrem JL; SJM DBS ET Study Group.

Parkinsonism Relat Disord. 2017 Jul;40:18-26. doi: 10.1016/j.parkreldis.2017.03.017. Epub 2017 Mar 30.

PMID:
28400200
4.

OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach.

Esquenazi A, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Graham GD, McGuire JR, Odderson IR, Patel AT, Simpson DM.

PM R. 2017 Mar 7. pii: S1934-1482(16)31113-3. doi: 10.1016/j.pmrj.2017.02.014. [Epub ahead of print]

5.

Poster 354 OnabotulinumtoxinA to Treat Common Postures in Post-Stroke Lower Limb Spasticity: Identification of a Treatment Paradigm.

Esquenazi A, Dashtipour K, Alfaro A, Ayyoub Z, Charles D, Graham GD, McGuire JR, Odderson IR, Patel AT, Simpson DM.

PM R. 2016 Sep;8(9S):S276. doi: 10.1016/j.pmrj.2016.07.523. Epub 2016 Sep 24. No abstract available.

PMID:
27673106
6.

Poster 203 Systematic Literature Review of AbobotulinumtoxinA in Randomized, Controlled Clinical Trials for Adult Lower Limb Spasticity.

Dashtipour K, Camba GC, Chen JJ, Walker HW, Lee MY.

PM R. 2016 Sep;8(9S):S227-S228. doi: 10.1016/j.pmrj.2016.07.241. Epub 2016 Sep 24. No abstract available.

PMID:
27672966
7.

Multilingual Sentiment Analysis: State of the Art and Independent Comparison of Techniques.

Dashtipour K, Poria S, Hussain A, Cambria E, Hawalah AY, Gelbukh A, Zhou Q.

Cognit Comput. 2016;8:757-771. Epub 2016 Jun 1.

8.

Novel Pattern of Iron Deposition in the Fascicula Nigrale in Patients with Parkinson's Disease: A Pilot Study.

Peckham ME, Dashtipour K, Holshouser BA, Kani C, Boscanin A, Kani K, Harder SL.

Radiol Res Pract. 2016;2016:9305018. doi: 10.1155/2016/9305018. Epub 2016 Jul 4.

9.

OnabotulinumtoxinA Injection for Poststroke Upper-Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process.

Simpson DM, Patel AT, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Esquenazi A, Graham GD, McGuire JR, Odderson I.

PM R. 2017 Feb;9(2):136-148. doi: 10.1016/j.pmrj.2016.06.016. Epub 2016 Jun 23.

10.

OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: a Systematic Literature Review.

Dashtipour K, Chen JJ, Espay AJ, Mari Z, Ondo W.

Mov Disord Clin Pract. 2016 Mar-Apr;3(2):109-115. Epub 2015 Oct 12.

11.

A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.

Han Y, Stevens AL, Dashtipour K, Hauser RA, Mari Z.

J Neurol. 2016 Apr;263(4):772-80. doi: 10.1007/s00415-016-8050-2. Epub 2016 Feb 25.

12.

Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile.

Dashtipour K, Pedouim F.

Semin Neurol. 2016 Feb;36(1):29-33. doi: 10.1055/s-0035-1571213. Epub 2016 Feb 11. Review.

PMID:
26866493
13.

Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Lower Limb Spasticity.

Dashtipour K, Chen JJ, Walker HW, Lee MY.

Medicine (Baltimore). 2016 Jan;95(2):e2468. doi: 10.1097/MD.0000000000002468. Review.

14.

Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm.

Dashtipour K, Chen JJ, Frei K, Nahab F, Tagliati M.

Tremor Other Hyperkinet Mov (N Y). 2015 Oct 30;5:338. doi: 10.7916/D8CJ8CVR. eCollection 2015. Review.

15.

Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study.

Dashtipour K, Chen JJ, Kani C, Bahjri K, Ghamsary M.

Pharmacotherapy. 2015 Jul;35(7):681-6. doi: 10.1002/phar.1611. Epub 2015 Jul 3.

16.

The Quantitative Measurement of Reversible Acute Depression after Subthalamic Deep Brain Stimulation in a Patient with Parkinson Disease.

Simmons DB, Dashtipour K.

Case Rep Neurol Med. 2015;2015:165846. doi: 10.1155/2015/165846. Epub 2015 May 18.

17.

Iron Accumulation Is Not Homogenous among Patients with Parkinson's Disease.

Dashtipour K, Liu M, Kani C, Dalaie P, Obenaus A, Simmons D, Gatto NM, Zarifi M.

Parkinsons Dis. 2015;2015:324843. doi: 10.1155/2015/324843. Epub 2015 Apr 5.

18.

Effect of exercise on motor and nonmotor symptoms of Parkinson's disease.

Dashtipour K, Johnson E, Kani C, Kani K, Hadi E, Ghamsary M, Pezeshkian S, Chen JJ.

Parkinsons Dis. 2015;2015:586378. doi: 10.1155/2015/586378. Epub 2015 Feb 2.

19.

Do genetic factors protect against Parkinson's disease? What I can learn from my healthy grandma.

Dashtipour K.

Med Hypotheses. 2014 Dec;83(6):637-9. doi: 10.1016/j.mehy.2014.09.024. Epub 2014 Oct 13.

PMID:
25459129
20.

Systematic literature review of abobotulinumtoxinA in clinical trials for adult upper limb spasticity.

Dashtipour K, Chen JJ, Walker HW, Lee MY.

Am J Phys Med Rehabil. 2015 Mar;94(3):229-38. doi: 10.1097/PHM.0000000000000208. Review.

Supplemental Content

Loading ...
Support Center